Name | FRAX1036 |
Description | FRAX-1036 is a effective and selective PAK1 inhibitor. |
Cell Research | MDA-MB175 cells are treated with increasing concentrations (0, 0.5, 1, 2.5, 5 μM) of FRAX1036 for 24 hours. |
Animal Research | Pak2-deficient mice were treated by oral gavage of 30 mg/kg Frax1036. |
In vitro | MDA-MB-175 cells,which are PAK1-amplified (MEK1-S298 and CRAF-S338) ,was observed Potent cellular inhibition at 2.5 to 5 μM concentrations of FRAX1036. PAK1-amplified breast cancer cells are treated with FRAX1036 leading to apoptosis. OVCAR-3 cells are treated with FRAX-1036 resulting in upregulation of p53 and p21, while down-regulating cyclin B1. |
In vivo | KT21 are treated with Frax1036 showing slower tumor growth, while Frax1036 is unlikely to have significant blood-brain barrier permeability in mice. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : insoluble
|
Keywords | FRAX1036 | Inhibitor | p21 activated kinases | PAK | inhibit | FRAX-1036 | FRAX 1036 |
Inhibitors Related | Fingolimod hydrochloride | ZINC194100678 | IPA-3 | PIR 3.5 | PF-3758309 hydrochloride | G-5555 | FRAX597 | NVS-PAK1-1 | GNE 2861 | 5-Aminosalicylic Acid | Fingolimod | FRAX486 HCL(1232030-35-1 free base) |
Related Compound Libraries | Bioactive Compound Library | Kinase Inhibitor Library | Inhibitor Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Cytoskeletal Signaling Pathway Compound Library |